{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:48:19Z","timestamp":1790819299092,"version":"4.1.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1,15]]},"DOI":"10.1097\/tp.0b013e31823ae7db","type":"journal-article","created":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T12:52:38Z","timestamp":1322743958000},"page":"73-81","source":"Crossref","is-referenced-by-count":81,"title":["Association of Immunosuppressive Maintenance Regimens With Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients"],"prefix":"10.1097","volume":"93","author":[{"given":"Marcelo Santos","family":"Sampaio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong W.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suphamai","family":"Bunnapradist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian V.","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210129","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJM200003023420901","article-title":"Improved graft survival after renal transplantation in the United States, 1988 to 1996.","volume":"342","author":"Hariharan","year":"2000","journal-title":"N Engl J Med"},{"key":"R2-12-20210129","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1600-6143.2010.03283.x","article-title":"Long-term renal allograft survival in the United States: A critical reappraisal.","volume":"11","author":"Lamb","year":"2011","journal-title":"Am J Transplant"},{"issue":"suppl 2","key":"R3-12-20210129","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.2215\/CJN.02900707","article-title":"Viral infection after renal transplantation: Surveillance and management.","volume":"3","author":"Weikert","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R4-12-20210129","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","article-title":"Cancer incidence before and after kidney transplantation.","volume":"296","author":"Vajdic","year":"2006","journal-title":"JAMA"},{"key":"R5-12-20210129","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11912-010-0132-1","article-title":"Post-transplantation lymphoproliferative disorders: Diagnosis, prognosis, and current approaches to therapy.","volume":"12","author":"Evens","year":"2010","journal-title":"Curr Oncol Rep"},{"key":"R6-12-20210129","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1128\/CMR.00006-09","article-title":"Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.","volume":"23","author":"Gulley","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"R7-12-20210129","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1111\/j.1600-6143.2008.02368.x","article-title":"Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients.","volume":"8","author":"Martinez","year":"2008","journal-title":"Am J Transplant"},{"key":"R8-12-20210129","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1600-6143.2006.01650.x","article-title":"Epstein-Barr virus: Evasive maneuvers in the development of PTLD.","volume":"7","author":"Snow","year":"2007","journal-title":"Am J Transplant"},{"key":"R9-12-20210129","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.trim.2008.08.005","article-title":"Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: Five-year outcomes.","volume":"20","author":"Anil Kumar","year":"2008","journal-title":"Transpl Immunol"},{"key":"R10-12-20210129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.tp.0000167757.63922.42","article-title":"A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 1 year.","volume":"80","author":"Mendez","year":"2005","journal-title":"Transplantation"},{"key":"R11-12-20210129","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/01.tp.0000203894.53714.27","article-title":"A randomized long-term trial of tacrolimus\/sirolimus versus tacrolimums\/mycophenolate versus cyclosporine\/sirolimus in renal transplantation: Three-year analysis.","volume":"81","author":"Ciancio","year":"2006","journal-title":"Transplantation"},{"key":"R12-12-20210129","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1399-0012.2007.00756.x","article-title":"Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen.","volume":"22","author":"Sampaio","year":"2008","journal-title":"Clin Transplant"},{"key":"R13-12-20210129","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","article-title":"Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.","volume":"28","author":"Smith","year":"2010","journal-title":"J Clin Oncol"},{"key":"R14-12-20210129","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/TP.0b013e318193886e","article-title":"The role of mTOR inhibitors in the management of posttransplant malignancy.","volume":"87","author":"Monaco","year":"2009","journal-title":"Transplantation"},{"key":"R15-12-20210129","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1097\/01.TP.0000063934.89714.19","article-title":"Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses.","volume":"75","author":"Majewski","year":"2003","journal-title":"Transplantation"},{"key":"R16-12-20210129","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.080068597","article-title":"The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders.","volume":"97","author":"Majewski","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"R17-12-20210129","first-page":"4472","article-title":"Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas.","volume":"63","author":"Nepomuceno","year":"2003","journal-title":"Cancer Res"},{"key":"R18-12-20210129","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/MOT.0b013e3283186ba9","article-title":"Epstein-Barr virus, rapamycin, and host immune responses.","volume":"13","author":"Krams","year":"2008","journal-title":"Curr Opin Organ Transplant"},{"key":"R19-12-20210129","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","article-title":"Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies.","volume":"18","author":"Mathew","year":"2004","journal-title":"Clin Transplant"},{"key":"R20-12-20210129","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1681\/ASN.2005090993","article-title":"Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.","volume":"17","author":"Campistol","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 1","key":"R21-12-20210129","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/ndt\/gfm088","article-title":"Post-transplant lymphoproliferative disorder\u2014The potential of proliferation signal inhibitors.","volume":"22","author":"Pascual","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R22-12-20210129","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1053\/j.ajkd.2006.01.029","article-title":"Sirolimus-induced remission of posttransplantation lymphoproliferative disorder.","volume":"47","author":"Cullis","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R23-12-20210129","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/j.transproceed.2007.05.046","article-title":"Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: Case reports.","volume":"39","author":"Iaria","year":"2007","journal-title":"Transplant Proc"},{"key":"R24-12-20210129","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.transproceed.2010.03.051","article-title":"Conversion to rapamycin immunosuppression for malignancy after kidney transplantation.","volume":"42","author":"Manuelli","year":"2010","journal-title":"Transplant Proc"},{"key":"R25-12-20210129","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1600-6143.2008.02167.x","article-title":"Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids.","volume":"8","author":"McDonald","year":"2008","journal-title":"Am J Transplant"},{"key":"R26-12-20210129","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1111\/j.1600-6143.2007.01972.x","article-title":"Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab.","volume":"7","author":"Kirk","year":"2007","journal-title":"Am J Transplant"},{"key":"R27-12-20210129","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.tp.0000179639.98338.39","article-title":"Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression.","volume":"80","author":"Caillard","year":"2005","journal-title":"Transplantation"},{"key":"R28-12-20210129","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/01.TP.0000081399.75231.3B","article-title":"Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression.","volume":"76","author":"Maluccio","year":"2003","journal-title":"Transplantation"},{"key":"R29-12-20210129","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: A collaborative transplant study report.","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"key":"R30-12-20210129","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1600-6135.2003.00274.x","article-title":"Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients.","volume":"4","author":"Bustami","year":"2004","journal-title":"Am J Transplant"},{"key":"R31-12-20210129","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/00007890-200104270-00010","article-title":"Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).","volume":"71","author":"Dharnidharka","year":"2001","journal-title":"Transplantation"},{"key":"R32-12-20210129","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2141.2010.08160.x","article-title":"Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients\u2014BCSH and BTS Guidelines.","volume":"149","author":"Parker","year":"2010","journal-title":"Br J Haematol"},{"key":"R33-12-20210129","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood-2009-02-202507","article-title":"Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation.","volume":"114","author":"van Leeuwen","year":"2009","journal-title":"Blood"},{"key":"R34-12-20210129","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1086\/514142","article-title":"Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: The role of cytomegalovirus disease.","volume":"176","author":"Ma\u00f1ez","year":"1997","journal-title":"J Infect Dis"},{"key":"R35-12-20210129","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1034\/j.1600-6143.2002.21019.x","article-title":"Post-transplant lymphoproliferative disorder in the United States: Young Caucasian males are at highest risk.","volume":"2","author":"Dharnidharka","year":"2002","journal-title":"Am J Transplant"},{"key":"R36-12-20210129","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1093\/ndt\/gfl134","article-title":"Switching immunosuppression medications after renal transplantation\u2014A common practice.","volume":"21","author":"Meier-Kriesche","year":"2006","journal-title":"Nephrol Dial Transplant"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/TP.0b013e31823ae7db","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:24:57Z","timestamp":1786047897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-201201150-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,15]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e31823ae7db","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1,15]]}}}